<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03259087</url>
  </required_header>
  <id_info>
    <org_study_id>3866-005</org_study_id>
    <secondary_id>CA22640</secondary_id>
    <secondary_id>MK-3866-005</secondary_id>
    <nct_id>NCT03259087</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)</brief_title>
  <official_title>A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV Dose to Subjects With Mild, Moderate, and Severe Renal Impairment and End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between&#xD;
      participants with impaired renal function and healthy control participants, to investigate&#xD;
      the extent to which MK-3866 is removed from the plasma by hemodialysis (HD), and evaluate the&#xD;
      safety and tolerability of MK-3866 in participants with impaired renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, 2-part single dose study: Part 1 will include participants with mild,&#xD;
      moderate, and severe renal impairment (as well as healthy control participants), and Part 2&#xD;
      will include participants with end stage renal disease (ESRD) undergoing HD. Participants in&#xD;
      Part 1 will receive a single IV dose of MK-3866, and plasma and urine samples will be&#xD;
      collected over pre-specified time intervals. Participants in Part 2 will receive a single IV&#xD;
      dose of MK-3866 on two separate occasions: in Period 1 immediately following their&#xD;
      normally-scheduled HD, and in Period 2 approximately 30 minutes prior to their&#xD;
      normally-scheduled HD. Plasma, urine, and dialysate samples will be collected over&#xD;
      pre-specified time intervals for Part 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">February 9, 2018</completion_date>
  <primary_completion_date type="Actual">January 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to the Time of the Last Quantifiable Sample (AUC0-last)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to 24 Hours After Dosing (AUC0-24)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1</time_frame>
    <description>Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma Concentration of MK-3866 at the End of the Infusion (Ceoi)</measure>
    <time_frame>At the end of the infusion (0.5 hours after infusion start) on Day 1</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum Plasma Concentration of MK-3866 (Cmax)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma Clearance of MK-3866 (CL)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Time to Maximum Plasma Concentration of MK-3866 (Tmax)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Elimination Terminal Half-life of Plasma MK-3866 (t1/2)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric % coefficient of variation (%CV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Volume of Distribution of Plasma MK-3866 (Vz)</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-inf of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-last of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC0-24 of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Ceoi of Plasma MK-3866</measure>
    <time_frame>At the end of the infusion (0.5 hours after infusion start) on Day 1 of Period 1 and Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: CL of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Tmax of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: t1/2 of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Vz of Plasma MK-3866</measure>
    <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Total Amount of MK-3866 Excreted in the Urine Over 24 Hours (Ae0-24)</measure>
    <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1</time_frame>
    <description>Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Renal Clearance (CLr) of MK-3866</measure>
    <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1</time_frame>
    <description>Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t&quot;)/AUC(t'-t&quot;), where t'-t&quot; is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)</measure>
    <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1</time_frame>
    <description>Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Total Amount of MK-3866 Excreted Unchanged in the Urine Over the Period of 24 Hours (Ae0-24)</measure>
    <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2</time_frame>
    <description>Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Renal Clearance (CLr) of MK-3866</measure>
    <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2</time_frame>
    <description>Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t&quot;)/AUC(t'-t&quot;), where t'-t&quot; is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)</measure>
    <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2</time_frame>
    <description>Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca)</measure>
    <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and Ca was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv)</measure>
    <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples exiting the dialyzer line were collected at pre-specified time points and Cv was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line During the Dialysis Period (AUCD)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUCD was assessed. AUCD values were determined from the Ca versus time profile during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Ca)</measure>
    <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Ca was assessed. AUC[0.75-4.5]Ca values were determined from the Ca versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Cv)</measure>
    <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Cv was assessed. AUC[0.75-4.5]Cv values were determined from the Cv versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Dialysis Clearance of MK-3866 Based on Plasma (CLD,Plasma)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma dialysis samples were collected at pre-specified time points and CLD was assessed. CLD was calculated as Q x R x (AUC[1-4.5]Ca - AUC[1-4.5]Cv) / AUC[1-4.5]Ca, where Q is the flow rate of blood through the dialyzer, and R is the ratio of blood drug concentration to plasma drug concentration. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Concentration of MK-3866 in Dialysate Samples (CD)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma dialysis samples were collected at pre-specified time points and CD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma dialysis samples were collected at pre-specified time points and AD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Rate of Removal of MK-3866 From the Dialysate (rr)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma dialysis samples were collected at pre-specified time points and rr was assessed. rr was calculated as CD x dialysate flow rate. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cumulative Amount of MK-3866 Recovered From the Dialysate (AD,Total)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma dialysis samples were collected at pre-specified time points and AD,total was assessed. AD,total was obtained by integrating the rr versus time profile over the dialysis session duration, using actual times relative to the start time of dialysis. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Hemodialysis Clearance of MK-3866 Based on the Dialysate(CLD,Dialysate)</measure>
    <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
    <description>Plasma dialysis samples were collected at pre-specified time points and CLD,dialysate was assessed. CLD,dialysate was calculated as AD.total / AUCD. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing the Study Due to an Adverse Event</measure>
    <time_frame>Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Part 1: Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: End-stage Renal Disease Undergoing Hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3866</intervention_name>
    <description>Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.</description>
    <arm_group_label>Part 1: Healthy Participants</arm_group_label>
    <arm_group_label>Part 1: Mild Renal Impairment</arm_group_label>
    <arm_group_label>Part 1: Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Part 1: Severe Renal Impairment</arm_group_label>
    <arm_group_label>Part 2: End-stage Renal Disease Undergoing Hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females of non-childbearing potential. Male participants with female partner(s) of&#xD;
             child-bearing potential agree to use a medically acceptable method of contraception&#xD;
             during the study and for 90 days after dosing. If partner is pregnant, males agree to&#xD;
             use a condom; if partner is of child-bearing potential, partner must use additional&#xD;
             birth control&#xD;
&#xD;
          -  Male participants agree not to donate sperm from the first dose until 90 days after&#xD;
             dosing&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
        Renal Impaired Participants&#xD;
&#xD;
          -  Liver function tests (serum alanine aminotransferase [ALT] and aspartate&#xD;
             aminotransferase [AST]) and serum bilirubin (total and direct) within upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Panels A, B, and C: no clinically significant change in renal status at least 1 month&#xD;
             prior to dosing and not currently or previously been on hemodialysis&#xD;
&#xD;
          -  Panel E only: ESRD maintained on stable regimen of at least 3 times per week HD for at&#xD;
             least 3 months prior to first dosing&#xD;
&#xD;
        Healthy Participants&#xD;
&#xD;
          -  Age within ± 15 years of the mean age of participants with impaired renal function to&#xD;
             which the healthy participant is matched&#xD;
&#xD;
          -  Medically healthy as per medical history, physical examination, vital signs, 12-lead&#xD;
             electrocardiograms (ECGs), and clinical laboratory safety tests&#xD;
&#xD;
          -  Blood urea nitrogen, liver function tests (ALT, AST, alkaline phosphatase [ALP]), and&#xD;
             serum bilirubin (total and direct) within upper limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mentally/legally incapacitated, or significant emotional problems or significant&#xD;
             psychiatric disorder&#xD;
&#xD;
          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,&#xD;
             hematological, hepatic, immunological, respiratory, genitourinary or major&#xD;
             neurological abnormalities or diseases&#xD;
&#xD;
          -  History of any illness that might confound the results of the study or poses an&#xD;
             additional risk to the participant by their participation in the study&#xD;
&#xD;
          -  Clinically significant history of cancer&#xD;
&#xD;
          -  Smoker and/or has used nicotine or nicotine-containing products within 3 months prior&#xD;
             to screening&#xD;
&#xD;
          -  Female participants of childbearing potential, pregnant, or lactating&#xD;
&#xD;
          -  Positive results for urine or saliva drug screen and/or urine or breath alcohol screen&#xD;
             at screening or check-in&#xD;
&#xD;
          -  Positive results at screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg), or hepatitis C virus (HCV)&#xD;
&#xD;
          -  Consumes more than 3 glasses of alcoholic beverages within 6 months of screening&#xD;
&#xD;
          -  Consumes excessive amounts of coffee, tea, cola, energy-drinks, or other caffeinated&#xD;
             beverages per day&#xD;
&#xD;
          -  Major surgery, donated or lost 1 unit of blood within 4 weeks prior to screening, or&#xD;
             donated plasma within 7 days prior to dosing in Part 1 or first dose in Part 2&#xD;
&#xD;
        Renal Impaired Participants&#xD;
&#xD;
          -  Panels A, B, and C: Failed renal transplant or has had nephrectomy&#xD;
&#xD;
          -  Panels A, B, and C: Rapidly fluctuating renal function, as determined by historical&#xD;
             measurements; or demonstrated/suspected renal artery stenosis&#xD;
&#xD;
          -  Panel E only: Has required frequent emergent HD (≥3) within a year prior to first&#xD;
             dosing&#xD;
&#xD;
        Healthy Participants&#xD;
&#xD;
          -  Renal transplant or nephrectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami ( Site 0001)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center ( Site 0002)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <results_first_submitted>January 25, 2019</results_first_submitted>
  <results_first_submitted_qc>January 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2019</results_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03259087/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Mild Renal Impairment (RI)</title>
          <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Moderate Renal Impairment</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Severe Renal Impairment</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: Healthy Participants</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 2: End-stage Renal Disease Undergoing Hemodialysis</title>
          <description>End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 and Period 1 of Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 of Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Period 2 did not apply to Part 1 participants</participants>
                <participants group_id="P2" count="0">Period 2 did not apply to Part 1 participants</participants>
                <participants group_id="P3" count="0">Period 2 did not apply to Part 1 participants</participants>
                <participants group_id="P4" count="0">Period 2 did not apply to Part 1 participants</participants>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Mild Renal Impairment (RI)</title>
          <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Moderate Renal Impairment</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: Severe Renal Impairment</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: Healthy Participants</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 2: End-stage Renal Disease Undergoing Hemodialysis</title>
          <description>End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="5.65"/>
                    <measurement group_id="B2" value="67.0" spread="9.24"/>
                    <measurement group_id="B3" value="57.3" spread="13.83"/>
                    <measurement group_id="B4" value="61.2" spread="8.36"/>
                    <measurement group_id="B5" value="51.9" spread="8.68"/>
                    <measurement group_id="B6" value="61.1" spread="10.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.125" lower_limit="20.00" upper_limit="36.00"/>
                    <measurement group_id="B2" value="27.625" lower_limit="23.00" upper_limit="34.00"/>
                    <measurement group_id="B3" value="28.625" lower_limit="20.00" upper_limit="32.00"/>
                    <measurement group_id="B4" value="28.800" lower_limit="27.00" upper_limit="30.00"/>
                    <measurement group_id="B5" value="29.875" lower_limit="27.00" upper_limit="34.00"/>
                    <measurement group_id="B6" value="28.619" lower_limit="20.00" upper_limit="36.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf)</title>
        <description>Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf)</title>
          <description>Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM*hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="87.2" upper_limit="125"/>
                    <measurement group_id="O2" value="141" lower_limit="115" upper_limit="174"/>
                    <measurement group_id="O3" value="83.5" lower_limit="75.0" upper_limit="92.9"/>
                    <measurement group_id="O4" value="244" lower_limit="169" upper_limit="352"/>
                    <measurement group_id="O5" value="81.8" lower_limit="72.4" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>2.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.20</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to the Time of the Last Quantifiable Sample (AUC0-last)</title>
        <description>Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to the Time of the Last Quantifiable Sample (AUC0-last)</title>
          <description>Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM*hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" lower_limit="86.7" upper_limit="123"/>
                    <measurement group_id="O2" value="139" lower_limit="114" upper_limit="170"/>
                    <measurement group_id="O3" value="83.0" lower_limit="74.5" upper_limit="92.5"/>
                    <measurement group_id="O4" value="237" lower_limit="166" upper_limit="338"/>
                    <measurement group_id="O5" value="81.4" lower_limit="72.0" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>2.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.17</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to 24 Hours After Dosing (AUC0-24)</title>
        <description>Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to 24 Hours After Dosing (AUC0-24)</title>
          <description>Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM*hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="82.0" upper_limit="113"/>
                    <measurement group_id="O2" value="127" lower_limit="107" upper_limit="152"/>
                    <measurement group_id="O3" value="79.7" lower_limit="71.6" upper_limit="88.7"/>
                    <measurement group_id="O4" value="182" lower_limit="136" upper_limit="243"/>
                    <measurement group_id="O5" value="78.1" lower_limit="69.2" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>2.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.82</ci_lower_limit>
            <ci_upper_limit>2.97</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Plasma Concentration of MK-3866 at the End of the Infusion (Ceoi)</title>
        <description>Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>At the end of the infusion (0.5 hours after infusion start) on Day 1</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Concentration of MK-3866 at the End of the Infusion (Ceoi)</title>
          <description>Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="22.3" upper_limit="31.8"/>
                    <measurement group_id="O2" value="27.7" lower_limit="24.2" upper_limit="31.7"/>
                    <measurement group_id="O3" value="27.0" lower_limit="23.9" upper_limit="30.5"/>
                    <measurement group_id="O4" value="29.7" lower_limit="25.4" upper_limit="34.7"/>
                    <measurement group_id="O5" value="26.9" lower_limit="23.7" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Maximum Plasma Concentration of MK-3866 (Cmax)</title>
        <description>Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the combined comparator experimental groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Healthy Participants (Mild, Moderate, and Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the mild, moderate, and severe groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Plasma Concentration of MK-3866 (Cmax)</title>
          <description>Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the combined comparator experimental groups.</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="26.0" upper_limit="28.9"/>
                    <measurement group_id="O2" value="28.0" lower_limit="26.4" upper_limit="29.7"/>
                    <measurement group_id="O3" value="28.7" lower_limit="26.4" upper_limit="31.2"/>
                    <measurement group_id="O4" value="26.7" lower_limit="24.8" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Plasma Clearance of MK-3866 (CL)</title>
        <description>Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Plasma Clearance of MK-3866 (CL)</title>
          <description>Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>L/hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="3.17" upper_limit="4.55"/>
                    <measurement group_id="O2" value="2.80" lower_limit="2.28" upper_limit="3.44"/>
                    <measurement group_id="O3" value="4.75" lower_limit="4.27" upper_limit="5.28"/>
                    <measurement group_id="O4" value="1.62" lower_limit="1.12" upper_limit="2.35"/>
                    <measurement group_id="O5" value="4.85" lower_limit="4.29" upper_limit="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Time to Maximum Plasma Concentration of MK-3866 (Tmax)</title>
        <description>Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time to Maximum Plasma Concentration of MK-3866 (Tmax)</title>
          <description>Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.47" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.47" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.47" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.47" upper_limit="0.53"/>
                    <measurement group_id="O5" value="0.50" lower_limit="0.47" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Elimination Terminal Half-life of Plasma MK-3866 (t1/2)</title>
        <description>Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric % coefficient of variation (%CV).</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Elimination Terminal Half-life of Plasma MK-3866 (t1/2)</title>
          <description>Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric % coefficient of variation (%CV).</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38" spread="13.3"/>
                    <measurement group_id="O2" value="8.23" spread="17.0"/>
                    <measurement group_id="O3" value="7.00" spread="12.7"/>
                    <measurement group_id="O4" value="14.7" spread="17.8"/>
                    <measurement group_id="O5" value="6.90" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Volume of Distribution of Plasma MK-3866 (Vz)</title>
        <description>Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Volume of Distribution of Plasma MK-3866 (Vz)</title>
          <description>Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="18.3"/>
                    <measurement group_id="O2" value="33.3" spread="18.0"/>
                    <measurement group_id="O3" value="48.0" spread="17.3"/>
                    <measurement group_id="O4" value="34.4" spread="29.5"/>
                    <measurement group_id="O5" value="48.3" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: AUC0-inf of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC0-inf of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM*hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323" lower_limit="260" upper_limit="401"/>
                    <measurement group_id="O2" value="129" lower_limit="103" upper_limit="161"/>
                    <measurement group_id="O3" value="81.3" lower_limit="70.6" upper_limit="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>3.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.26</ci_lower_limit>
            <ci_upper_limit>4.82</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: AUC0-last of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC0-last of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM*hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294" lower_limit="241" upper_limit="358"/>
                    <measurement group_id="O2" value="118" lower_limit="97.4" upper_limit="144"/>
                    <measurement group_id="O3" value="80.9" lower_limit="70.2" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>3.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.03</ci_lower_limit>
            <ci_upper_limit>4.36</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: AUC0-24 of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: AUC0-24 of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM*hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="174" upper_limit="238"/>
                    <measurement group_id="O2" value="84.7" lower_limit="74.6" upper_limit="96.1"/>
                    <measurement group_id="O3" value="77.8" lower_limit="67.5" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>2.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Ceoi of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>At the end of the infusion (0.5 hours after infusion start) on Day 1 of Period 1 and Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Ceoi of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="22.7" upper_limit="30.3"/>
                    <measurement group_id="O2" value="25.3" lower_limit="19.1" upper_limit="33.4"/>
                    <measurement group_id="O3" value="26.8" lower_limit="23.1" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Cmax of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Cmax of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>µM</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="23.1" upper_limit="30.6"/>
                    <measurement group_id="O2" value="25.3" lower_limit="19.1" upper_limit="33.4"/>
                    <measurement group_id="O3" value="26.8" lower_limit="23.1" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: CL of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: CL of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.989" upper_limit="1.53"/>
                    <measurement group_id="O2" value="3.08" lower_limit="2.47" upper_limit="3.85"/>
                    <measurement group_id="O3" value="4.87" lower_limit="4.23" upper_limit="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Tmax of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Tmax of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.50" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.50" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.48" lower_limit="0.47" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: t1/2 of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: t1/2 of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="21.6"/>
                    <measurement group_id="O2" value="20.0" spread="18.0"/>
                    <measurement group_id="O3" value="6.81" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Vz of Plasma MK-3866</title>
        <description>Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Vz of Plasma MK-3866</title>
          <description>Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="20.0"/>
                    <measurement group_id="O2" value="89.1" spread="12.2"/>
                    <measurement group_id="O3" value="47.9" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Total Amount of MK-3866 Excreted in the Urine Over 24 Hours (Ae0-24)</title>
        <description>Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Total Amount of MK-3866 Excreted in the Urine Over 24 Hours (Ae0-24)</title>
          <description>Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>mg</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="79.6" upper_limit="118"/>
                    <measurement group_id="O2" value="69.2" lower_limit="48.4" upper_limit="98.8"/>
                    <measurement group_id="O3" value="107" lower_limit="89.0" upper_limit="130"/>
                    <measurement group_id="O4" value="34.6" lower_limit="22.7" upper_limit="52.6"/>
                    <measurement group_id="O5" value="115" lower_limit="96.4" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Renal Clearance (CLr) of MK-3866</title>
        <description>Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t&quot;)/AUC(t'-t&quot;), where t'-t&quot; is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Renal Clearance (CLr) of MK-3866</title>
          <description>Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t&quot;)/AUC(t'-t&quot;), where t'-t&quot; is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>L/hr</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.50" upper_limit="2.66"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.801" upper_limit="1.45"/>
                    <measurement group_id="O3" value="2.67" lower_limit="2.18" upper_limit="3.27"/>
                    <measurement group_id="O4" value="0.377" lower_limit="0.200" upper_limit="0.710"/>
                    <measurement group_id="O5" value="2.92" lower_limit="2.33" upper_limit="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)</title>
        <description>Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (Mild + Moderate RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the combined mild and moderate RI groups</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Healthy Participants (Severe RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the severe RI group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)</title>
          <description>Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Fraction of MK-3866 Excreted</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.485" lower_limit="0.398" upper_limit="0.592"/>
                    <measurement group_id="O2" value="0.346" lower_limit="0.242" upper_limit="0.494"/>
                    <measurement group_id="O3" value="0.537" lower_limit="0.445" upper_limit="0.648"/>
                    <measurement group_id="O4" value="0.173" lower_limit="0.114" upper_limit="0.263"/>
                    <measurement group_id="O5" value="0.575" lower_limit="0.482" upper_limit="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio (GMR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>GMR is ratio of Experimental Group / Healthy Group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Total Amount of MK-3866 Excreted Unchanged in the Urine Over the Period of 24 Hours (Ae0-24)</title>
        <description>Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Total Amount of MK-3866 Excreted Unchanged in the Urine Over the Period of 24 Hours (Ae0-24)</title>
          <description>Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="42.6"/>
                    <measurement group_id="O2" value="2.21" spread="4.4"/>
                    <measurement group_id="O3" value="115" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Renal Clearance (CLr) of MK-3866</title>
        <description>Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t&quot;)/AUC(t'-t&quot;), where t'-t&quot; is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Renal Clearance (CLr) of MK-3866</title>
          <description>Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t&quot;)/AUC(t'-t&quot;), where t'-t&quot; is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0474" spread="8.5"/>
                    <measurement group_id="O2" value="0.0558" spread="15.8"/>
                    <measurement group_id="O3" value="2.92" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)</title>
        <description>Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Healthy Participants (ESRD)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the ESRD group.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)</title>
          <description>Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Fraction of MK-3866 Excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0216" spread="42.6"/>
                    <measurement group_id="O2" value="0.0111" spread="4.4"/>
                    <measurement group_id="O3" value="0.574" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca)</title>
        <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and Ca was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca)</title>
          <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and Ca was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv)</title>
        <description>Plasma samples exiting the dialyzer line were collected at pre-specified time points and Cv was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv)</title>
          <description>Plasma samples exiting the dialyzer line were collected at pre-specified time points and Cv was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>µM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.32" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line During the Dialysis Period (AUCD)</title>
        <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUCD was assessed. AUCD values were determined from the Ca versus time profile during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line During the Dialysis Period (AUCD)</title>
          <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUCD was assessed. AUCD values were determined from the Ca versus time profile during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Ca)</title>
        <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Ca was assessed. AUC[0.75-4.5]Ca values were determined from the Ca versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Ca)</title>
          <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Ca was assessed. AUC[0.75-4.5]Ca values were determined from the Ca versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Cv)</title>
        <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Cv was assessed. AUC[0.75-4.5]Cv values were determined from the Cv versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Cv)</title>
          <description>Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Cv was assessed. AUC[0.75-4.5]Cv values were determined from the Cv versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Dialysis Clearance of MK-3866 Based on Plasma (CLD,Plasma)</title>
        <description>Plasma dialysis samples were collected at pre-specified time points and CLD was assessed. CLD was calculated as Q x R x (AUC[1-4.5]Ca - AUC[1-4.5]Cv) / AUC[1-4.5]Ca, where Q is the flow rate of blood through the dialyzer, and R is the ratio of blood drug concentration to plasma drug concentration. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Dialysis Clearance of MK-3866 Based on Plasma (CLD,Plasma)</title>
          <description>Plasma dialysis samples were collected at pre-specified time points and CLD was assessed. CLD was calculated as Q x R x (AUC[1-4.5]Ca - AUC[1-4.5]Cv) / AUC[1-4.5]Ca, where Q is the flow rate of blood through the dialyzer, and R is the ratio of blood drug concentration to plasma drug concentration. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="201.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Concentration of MK-3866 in Dialysate Samples (CD)</title>
        <description>Plasma dialysis samples were collected at pre-specified time points and CD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Concentration of MK-3866 in Dialysate Samples (CD)</title>
          <description>Plasma dialysis samples were collected at pre-specified time points and CD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>µM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" spread="0.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.894" spread="0.0896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.695" spread="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.542" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD)</title>
        <description>Plasma dialysis samples were collected at pre-specified time points and AD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD)</title>
          <description>Plasma dialysis samples were collected at pre-specified time points and AD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.946" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.736" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.576" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.408" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.327" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.272" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.224" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.173" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.158" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Rate of Removal of MK-3866 From the Dialysate (rr)</title>
        <description>Plasma dialysis samples were collected at pre-specified time points and rr was assessed. rr was calculated as CD x dialysate flow rate. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Rate of Removal of MK-3866 From the Dialysate (rr)</title>
          <description>Plasma dialysis samples were collected at pre-specified time points and rr was assessed. rr was calculated as CD x dialysate flow rate. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>mg/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Cumulative Amount of MK-3866 Recovered From the Dialysate (AD,Total)</title>
        <description>Plasma dialysis samples were collected at pre-specified time points and AD,total was assessed. AD,total was obtained by integrating the rr versus time profile over the dialysis session duration, using actual times relative to the start time of dialysis. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Cumulative Amount of MK-3866 Recovered From the Dialysate (AD,Total)</title>
          <description>Plasma dialysis samples were collected at pre-specified time points and AD,total was assessed. AD,total was obtained by integrating the rr versus time profile over the dialysis session duration, using actual times relative to the start time of dialysis. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Hemodialysis Clearance of MK-3866 Based on the Dialysate(CLD,Dialysate)</title>
        <description>Plasma dialysis samples were collected at pre-specified time points and CLD,dialysate was assessed. CLD,dialysate was calculated as AD.total / AUCD. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
        <time_frame>0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2</time_frame>
        <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Hemodialysis Clearance of MK-3866 Based on the Dialysate(CLD,Dialysate)</title>
          <description>Plasma dialysis samples were collected at pre-specified time points and CLD,dialysate was assessed. CLD,dialysate was calculated as AD.total / AUCD. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.</description>
          <population>All participants who received MK-3866 infusion and provided samples for the outcome. This outcome applied only to ESRD participants receiving HD after infusion of MK-3866 (Part 2, Period 2).</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Adverse Event (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Healthy Participants</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Event (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing the Study Due to an Adverse Event</title>
        <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing</time_frame>
        <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Mild Renal Impairment (RI)</title>
            <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Moderate Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Severe Renal Impairment</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O5">
            <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Healthy Participants</title>
            <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender and mean age and BMI of the comparator groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing the Study Due to an Adverse Event</title>
          <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing</time_frame>
      <desc>All participants who received MK-3866 infusion. Healthy participants were those who matched gender, and mean age and BMI of the comparator experimental group(s).</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Mild Renal Impairment (RI)</title>
          <description>Participants received a single intravenous (IV) infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Moderate Renal Impairment</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Severe Renal Impairment</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 2, Period 1: ESRD Undergoing HD (Dosed After HD)</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after HD in Period 1. There was a washout of at least 6 days before dosing in Period 2.</description>
        </group>
        <group group_id="E5">
          <title>Part 2, Period 2: ESRD Undergoing HD (Dosed Before HD)</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: Healthy Participants</title>
          <description>Participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1. These healthy participants matched the gender, and mean age and BMI of the comparator groups.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor will provide separate guidance on the criteria for publication of clinical trial data when contacted for permission to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03259087
org study id: 3866-005
secondary id: CA22640
secondary id: MK-3866-005
nct id: NCT03259087
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between
      participants with impaired renal function and healthy control participants, to investigate
      the extent to which MK-3866 is removed from the plasma by hemodialysis (HD), and evaluate the
      safety and tolerability of MK-3866 in participants with impaired renal function.
This is an open-label, 2-part single dose study: Part 1 will include participants with mild,
      moderate, and severe renal impairment (as well as healthy control participants), and Part 2
      will include participants with end stage renal disease (ESRD) undergoing HD. Participants in
      Part 1 will receive a single IV dose of MK-3866, and plasma and urine samples will be
      collected over pre-specified time intervals. Participants in Part 2 will receive a single IV
      dose of MK-3866 on two separate occasions: in Period 1 immediately following their
      normally-scheduled HD, and in Period 2 approximately 30 minutes prior to their
      normally-scheduled HD. Plasma, urine, and dialysate samples will be collected over
      pre-specified time intervals for Part 2.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).
measure: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to the Time of the Last Quantifiable Sample (AUC0-last)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to 24 Hours After Dosing (AUC0-24)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1
description: Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Plasma Concentration of MK-3866 at the End of the Infusion (Ceoi)
time frame: At the end of the infusion (0.5 hours after infusion start) on Day 1
description: Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Maximum Plasma Concentration of MK-3866 (Cmax)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Plasma Clearance of MK-3866 (CL)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Time to Maximum Plasma Concentration of MK-3866 (Tmax)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Elimination Terminal Half-life of Plasma MK-3866 (t1/2)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric % coefficient of variation (%CV).
measure: Part 1: Volume of Distribution of Plasma MK-3866 (Vz)
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, and 48 hours after dosing on Day 1, and 60 and 72 hours after dosing for Severe Renal Impairment participants
description: Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: AUC0-inf of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and AUC0-inf was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: AUC0-last of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and AUC0-last was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: AUC0-24 of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, and 24 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and AUC0-24 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: Ceoi of Plasma MK-3866
time frame: At the end of the infusion (0.5 hours after infusion start) on Day 1 of Period 1 and Period 2
description: Plasma samples were collected at pre-specified time points and Ceoi was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: Cmax of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and Cmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: CL of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and CL was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: Tmax of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and Tmax was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1.
measure: Part 2: t1/2 of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and t1/2 was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Vz of Plasma MK-3866
time frame: Predose and 0.5, 0.75, 1, 1.5, 2, 3, 4.5, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing on Day 1 of Period 1 and 2, and 2.5, 3.5, and 4 hours after dosing on Day 1 of Period 2
description: Plasma samples were collected at pre-specified time points and Vz was assessed. Plasma concentrations of MK-3866 were determined using HPLC-MS/MS. For ESRD participants, hemodialysis took place predose in Period 1 and from 0.5 to 4.5 hours after dosing in Period 2. Data for healthy participants are from Part 1. Method of dispersion used for these data is geometric %CV.
measure: Part 1: Total Amount of MK-3866 Excreted in the Urine Over 24 Hours (Ae0-24)
time frame: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1
description: Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Renal Clearance (CLr) of MK-3866
time frame: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1
description: Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t")/AUC(t'-t"), where t'-t" is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 1: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)
time frame: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1
description: Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 2: Total Amount of MK-3866 Excreted Unchanged in the Urine Over the Period of 24 Hours (Ae0-24)
time frame: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2
description: Urine samples were collected at pre-specified intervals and Ae0-24 was assessed. Ae0-24 was obtained by adding the amounts excreted over each collection interval. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Renal Clearance (CLr) of MK-3866
time frame: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2
description: Urine samples were collected at pre-specified intervals and CLr was assessed. CLr was calculated as AE(t'-t")/AUC(t'-t"), where t'-t" is the longest interval of time during which AE and AUC are both obtained. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Fraction of MK-3866 Excretion (Urine) During Each Collection Interval (Fe0-24)
time frame: Predose and 0-4, 4-8, 8-12, and 12-24 hours after dosing on Day 1 of Period 1 and Period 2
description: Urine samples were collected at pre-specified intervals and Fe0-24 was assessed. Fe0-24 was obtained by dividing the amount of MK-3866 excreted in each collection interval by the dose. Urine concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Concentration of MK-3866 in Plasma Entering the Dialyzer Line (Ca)
time frame: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma samples entering the dialyzer line were collected at pre-specified time points and Ca was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Concentration of MK-3866 in Plasma Exiting the Dialyzer Line (Cv)
time frame: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma samples exiting the dialyzer line were collected at pre-specified time points and Cv was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line During the Dialysis Period (AUCD)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma samples entering the dialyzer line were collected at pre-specified time points and AUCD was assessed. AUCD values were determined from the Ca versus time profile during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Ca)
time frame: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Ca was assessed. AUC[0.75-4.5]Ca values were determined from the Ca versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Area Under the Concentration-time Curve of MK-3866 in Plasma Entering the Dialyzer Line From 0.75 to 4.5 Hours During the Dialysis Period (AUC[0.75-4.5]Cv)
time frame: 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma samples entering the dialyzer line were collected at pre-specified time points and AUC[0.75-4.5]Cv was assessed. AUC[0.75-4.5]Cv values were determined from the Cv versus time profile from 0.75 to 4.5 hours during the HD period, using the 'linear up, log down' calculation method. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Dialysis Clearance of MK-3866 Based on Plasma (CLD,Plasma)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma dialysis samples were collected at pre-specified time points and CLD was assessed. CLD was calculated as Q x R x (AUC[1-4.5]Ca - AUC[1-4.5]Cv) / AUC[1-4.5]Ca, where Q is the flow rate of blood through the dialyzer, and R is the ratio of blood drug concentration to plasma drug concentration. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Concentration of MK-3866 in Dialysate Samples (CD)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma dialysis samples were collected at pre-specified time points and CD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS.
measure: Part 2: Amount of MK-3866 Recovered From Each Dialysate Sample (AD)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma dialysis samples were collected at pre-specified time points and AD was assessed. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Rate of Removal of MK-3866 From the Dialysate (rr)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma dialysis samples were collected at pre-specified time points and rr was assessed. rr was calculated as CD x dialysate flow rate. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Cumulative Amount of MK-3866 Recovered From the Dialysate (AD,Total)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma dialysis samples were collected at pre-specified time points and AD,total was assessed. AD,total was obtained by integrating the rr versus time profile over the dialysis session duration, using actual times relative to the start time of dialysis. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Part 2: Hemodialysis Clearance of MK-3866 Based on the Dialysate(CLD,Dialysate)
time frame: 0.5 (beginning of HD), 1, 1.5, 2, 2.5, 3, 3.5, 4, and 4.5 hours after dosing on Day 1 of Period 2
description: Plasma dialysis samples were collected at pre-specified time points and CLD,dialysate was assessed. CLD,dialysate was calculated as AD.total / AUCD. Concentrations of MK-3866 were determined using HPLC-MS/MS. Method of dispersion used for these data is geometric %CV.
measure: Number of Participants With at Least One Adverse Event (AE)
time frame: Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing
description: An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
measure: Number of Participants Discontinuing the Study Due to an Adverse Event
time frame: Part 1: up to Day 14 after dosing; Part 2, Period 1: up to Day 14 after dosing (including ≥6 day washout period); Part 2, Period 2: up to Day 14 after dosing
description: An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
arm group label: Part 1: Mild Renal Impairment
arm group type: Experimental
description: Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
arm group label: Part 1: Moderate Renal Impairment
arm group type: Experimental
description: Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
arm group label: Part 1: Severe Renal Impairment
arm group type: Experimental
description: Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
arm group label: Part 1: Healthy Participants
arm group type: Experimental
description: Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
arm group label: Part 2: End-stage Renal Disease Undergoing Hemodialysis
arm group type: Experimental
description: End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
intervention type: Drug
intervention name: MK-3866
description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
arm group label: Part 1: Healthy Participants
arm group label: Part 1: Mild Renal Impairment
arm group label: Part 1: Moderate Renal Impairment
arm group label: Part 1: Severe Renal Impairment
arm group label: Part 2: End-stage Renal Disease Undergoing Hemodialysis
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Medical Director
role: Study Director
affiliation: Merck Sharp & Dohme LLC
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Renal Insufficiency
sharing ipd: Yes
ipd description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
ipd url: http://engagezone.msd.com/ds_documentation.php
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 